Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Active-Controlled Trial of AXS-05 Administered Orally to Subjects With Major Depressive Disorder

Trial Profile

Randomized, Double-Blind, Active-Controlled Trial of AXS-05 Administered Orally to Subjects With Major Depressive Disorder

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Acronyms ASCEND
  • Sponsors Axsome Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to an Axsome Therapeutics media release, detailed results of this study are expected to be presented at upcoming scientific meetings.
    • 07 Jan 2019 Primary endpoint has been met (The Montgomery-Asberg Depression Rating Scale (MADRS) total score as compared to bupropion ), according to an Axsome Therapeutics media release.
    • 07 Jan 2019 Results presented in an Axsome Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top